Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:
- 24,701 shares
- €2,635,980.25
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between July 1st, 2024 and December 31st, 2024 have been executed:
- 2,936 purchase transactions
- 2,346 sell transactions
Under the same period, the volumes traded represented:
- 311,792 shares and €33,997,824.80 to the purchase
- 321,682 shares and €35,215,771.10 to the sel
Attachment

Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:
- 24,701 shares
- €2,635,980.25
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between July 1st, 2024 and December 31st, 2024 have been executed:
- 2,936 purchase transactions
- 2,346 sell transactions
Under the same period, the volumes traded represented:
- 311,792 shares and €33,997,824.80 to the purchase
- 321,682 shares and €35,215,771.10 to the sel
Attachment

Related stories
Des données aux décisions : comment Ipsen transforme les données médicales en actions pour les patients
Ipsen récompensé aux LTEN Excellence Awards 2026 pour la transformation du leadership terrain par le coaching
Renforcer les partenariats avec les organisations de patients : enseignements et opportunités de progrès
Related Press Releases
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – May 2026 – Monthly information relative to the...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen announces the launch of an Employee Shareholding Plan
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – April 2026- Monthly information relative to the total...